BioMarin Pharmaceuticals BMRN Products excluding ALDURAZYME — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's products excluding aldurazyme — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported products excluding ALDURAZYME — total revenues of $723.34M in Q1 2026.
- How has BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues increased by 5.5% year-over-year, from $685.67M to $723.34M.
- What is the long-term trend for BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's products excluding ALDURAZYME — total revenues has grown at a 15.5% compound annual growth rate (CAGR), from $1.66B to $2.96B.
- What does products excluding ALDURAZYME — total revenues mean?
- The total sales revenue generated by the company's independently marketed rare-disease products, excluding the Aldurazyme joint venture.
- How do you interpret products excluding ALDURAZYME — total revenues?
- An increase indicates successful commercialization and market penetration of the company's core proprietary drug portfolio. A decrease may signal competitive pressure, patent expirations, or challenges in patient access and reimbursement for these specific therapies.
- How does products excluding ALDURAZYME — total revenues compare across companies?
- Comparable to core product revenue segments in other biotechnology firms that focus on orphan drugs and specialty pharmaceuticals, excluding revenue from collaborative or licensed-out arrangements.